Precision medicine for ovarian clear cell carcinoma based on gene alterations.
Takafumi KurodaTakashi KohnoPublished in: International journal of clinical oncology (2020)
Ovarian clear cell carcinoma (OCCC) is a histological subtype of epithelial ovarian carcinoma prevalent in Asians. No clear therapeutic selection based on molecular profile has been implemented for this disease. Oncogenic PIK3CA mutation, which activates the PIK3CA/AKT/mTOR signaling pathway, is a promising druggable alteration in OCCC. Recent studies by our group and others have identified the ARID1A mutation as another alteration linked to therapeutic selection based on synthetic lethality: deleterious ARID1A mutations, resulting in ARID1A deficiency, make OCCC cells sensitive to drugs targeting poly (ADP-ribose) polymerase and EZH2, as well as to glutathione inhibitors. In addition, we recently obtained evidence that ARID1A-deficient OCCC could benefit from gemcitabine treatment. Precision medicine based on gene alteration profiling might improve the prognosis of OCCC patients.
Keyphrases
- clear cell
- signaling pathway
- induced apoptosis
- end stage renal disease
- cell proliferation
- copy number
- chronic kidney disease
- newly diagnosed
- ejection fraction
- cell cycle arrest
- pi k akt
- genome wide
- epithelial mesenchymal transition
- prognostic factors
- single cell
- oxidative stress
- protein kinase
- gene expression
- endoplasmic reticulum stress
- squamous cell carcinoma
- replacement therapy
- cell death